Elizabeth Daniel, MD
Allergy & Immunology · Pikesville, MDNPI 1679991954
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 406 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,334 and has fallen 97.2% since, to $95 in 2025.
Across 406 payments — averaging $22.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Sanofi$1K
- AstraZeneca$901
- Regeneron Healthcare Solutions, Inc.$746
- Optinose US, Inc.$514
- Takeda Pharmaceuticals U.S.A., Inc.$495
- plus $4K from 22 others
What the payments were for
- Food & beverage$8,92499%
- Education$981%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 66 | $1,298 |
| Sanofi | 36 | $1,154 |
| AstraZeneca | 47 | $901 |
| Regeneron Healthcare Solutions, Inc. | 34 | $746 |
| Optinose US, Inc. | 21 | $514 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $495 |
| Amgen(2 entities) | 17 | $483 |
| CSL Behring | 22 | $435 |
| Pfizer | 18 | $375 |
| Genentech USA, Inc. | 14 | $355 |
| Teva Pharmaceuticals USA, Inc. | 19 | $326 |
| Novartis | 14 | $298 |
| Kaleo, Inc. | 13 | $274 |
| Grifols USA, LLC | 13 | $238 |
| AbbVie | 11 | $213 |
| Biocryst US Sales Co., LLC | 7 | $193 |
| Incyte Corporation | 10 | $187 |
| Alk-abello, Inc | 2 | $130 |
| Aimmune Therapeutics, Inc. | 6 | $103 |
| Sanofi-aventis U.S. LLC | 2 | $82 |
| Boehringer Ingelheim | 3 | $54 |
| Phadia US Inc. | 2 | $47 |
| Merck | 2 | $29 |
| Galderma Laboratories, L.p. | 1 | $24 |
| Genentech, Inc. | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Blueprint Medicines Corporation | 1 | $15 |
| Mylan Specialty L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,023 in reported general payments places this provider in the 75th percentile of 105 allergy & immunology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 16 | $456 |
| Fluticasone Propionate | 14 | $139 |
| Montelukast Sodium | 12 | $80 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Pikesville
- Sangeeta JainPikesville$5K
- Antoine AzarBaltimore$612K
- Mark ScarupaWheaton$508K
- Sally BaileyBaltimore$344K
- Manav SinglaWhite Marsh$168K
- Sudhir SekhsariaRockville$87K
- Nasim ReedyGaithersburg$63K
- Kristin SokolRockville$62K
- Rachel SchreiberRockville$48K
- Eric OliverBaltimore$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.